If I recall correctly, the IP associated with therapeutic use of Apo A1 Milano still resides in the sub-basement of Pfizer as a result of the Esperion purchase?
It was licensed by MDCO in late 2009 (#msg-44863685).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.